Bioptigen’s High-resolution Spectral-domain Optical Coherence Tomography Imaging for Clinical and Pre-clinical Research Applications

Abstract

Bioptigen spectral-domain optical coherence tomography (SDOCT) is leading the development of OCT for applications in clinical and pre-clinical research applications. Bioptigen's exceptional image quality, fully customizable highspeed image acquisition, and versatility of scanning optics combine in the only SDOCT system suitable for use from the clinic to the operating suite, for neonatal patients to adult, and for non-invasive imaging of animal models in the research lab. TechnologySDOCT is a second-generation imaging technology that is rapidly changing the face of ophthalmic disease management. OCT fills a niche between microscopy and ultrasound as an imaging modality that enables the depth-resolved imaging of tissue microstructure with axial and lateral resolution on the micron level. Images acquired on Bioptigen's 840nm ophthalmic SDOCT systems demonstrate an unmatched level of detail, owing to depth-independent axial resolution of 4.5 microns and lateral resolution at the retina of 20 microns. Bioptigen's system is ready for the future, with an upgrade option for ultrahigh-resolution imaging down to three microns.Bioptigen ophthalmic SDOCT systems acquire, process, and display images at 17,000 lines. This image acquisition rate results in a reduction of the number of motion artifacts, eliminating the need to normalize distortions in cross-sectional B-scans caused by patient motion. High-density 1,000-line images are acquired at 17 frames per second, and high-density volumes of 100,000 lateral positions are acquired in just six seconds. System SpecificationsBioptigen SDOCT is designed to provide the researcher, physician, and patient with the most advanced set of imaging tools to diagnose and treat eye disease from the very earliest stages. Resolving power is critical for assessing early symptoms of eye disease, whether it is the formation of drusen in early-stage age-related macular degeneration (AMD), the onset of choroidal neovascularization (CNV), and fractional changes in retinal edema or retinal nerve fibre layer (RNFL) thicknesses. Bioptigen systems provide 4.5-micron resolution for imaging the retina from the inner retina through to the choroid, or for high-resolution imaging of anterior structures such as the cornea, the sclera, and the angle. Superior imaging depth provides dramatic images of the optic nerve head through to the lamina cribosa. A simple change in optics allows for imaging of anterior structures such as the cornea and sclera, enabling the imaging of features such as Bowman's membrane in the cornea and Schlemm's canal at the angle. Further, the Bioptigen system is compatible with every broadband sources, providing resolution better than 3 microns; ultra high-resolution sources are available as an option. Bioptigen high-resolution systems are ideally suited for glaucoma and macular analysis, and for tracking disease change in combination with drug, laser, or surgical therapy.These performance advantages are brought to a broader patient and subject base through unmatched system versatili...

Examination under anesthesia: Preferred Practice

“…Various portable, noncontact, handheld SD-OCT devices are available, such as the Bioptigen Inc., OptoVue iVue, and so on. [ 41 ] It consists of an imaging handpiece connected via a 1.3 m flexible cable to an SD-OCT engine. The probe has a wide focus range of +10 D to −12 D. The time to image a single eye should not be more than 5 min.…”

“…A separate coupling agent need not be used; artificial lubricants or saline drops generally serve the purpose. [ 41 ] Some deep focus models are also newly available which enable better visualization of the angles. [ 41 ] This is useful in the diagnosis of macular conditions such as foveal hypoplasia, inherited and pigmentary retinal dystrophies, macular dystrophies, and their prognostication.…”